Gene-silencing to curb LDL-C ‘could dramatically cut CVD risk’
Researchers have attempted to simulate a 50-year randomised controlled trial.
AusDoc brings you the latest news from the European Society of Cardiology Congress 2021.
Having an annual ‘vaccination’ from the age of 30 to reduce LDL-cholesterol (LDL-C) levels could have a dramatic effect on the risk of major cardiovascular events, UK researchers say.
Furthermore, they say that reduction of the cumulative exposure to LDL-C is the key factor in curbing atherosclerosis.
Speaking to delegates at the ESC Congress 2021, Professor Brian Ference of the University of Cambridge, UK, described the results of computer modelling to simulate a 50-year-long clinical trial of the strategy, using data from the UK Biobank.
